Obesity
🇺🇸 FDA Page 3FDA news and analysis for pharmaceutical BD, investment, and market access · 10 articles on this page
Gain critical insights into global obesity drug development, market trends, and regulatory landscapes. Drive your pharma strategy with NovaPharmaNews intelligence.
Showing 25–34 of 34 articles
FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
Mounjaro FDA Approval Obesity: Eli Lilly's Tirzepatide Awaits
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Viking Therapeutics VK2735 Phase 3 Obesity Trials Fully Enrolled as Company Reports Q1 2026 Results
Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies
FormBlends Releases 2026 Peptide Report as RFK-Era HHS Reshapes GLP-1 Therapy Access
GLP-1 Eating Disorder Risk: What You Need to Know
Corbus Pharmaceuticals CRB-913 Obesity Drug Completes Patient Enrollment in CANYON-1 Phase 1b Trial
FDA Approves Higher-Dose Wegovy 7.2mg for Weight Loss Under Priority Review Program